Combination therapy for treatment of cancer
AssigneeAVEO Pharmaceuticals, Inc.
InventorJulie E. Bauman
Life of this patent
Estimating the term…
Abstract
The present invention provides improved methods of treating subjects with cancers, such as head and neck squamous cell carcinoma (HNSCC). In one aspect, the invention provides a method of treating cancer in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of an HGF inhibitor and an EGFR inhibitor. In some embodiments, recurrent or metastatic HNSCC is treated with a combination of ficlatuzumab and cetuximab.
Claims40
A method of treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in a subject
- having recurrent or metastatic HNSCC that is human papillomavirus (HPV) negative,
- the method comprising administering to the subject an effective amount of cetuximab with an effective amount of ficlatuzumab, thereby treating the HNSCC that is HPV negative.
(canceled)
4-7. (canceled)
(canceled)
11-20. (canceled)
(canceled)
25-27. (canceled)
29-35. (canceled)
37-38. (canceled)
A method of identifying a subject with head and neck squamous cell carcinoma (HNSCC) that is suitable for a combination therapy with ficlatuzumab and cetuximab, the method comprising assessing whether the HNSCC is human papillomavirus (HPV)-negative or HPV-positive.
(canceled)
42-64. (canceled)
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-HGF antibody or antigen binding fragment thereof and an anti-EGFR antibody or antigen binding fragment thereof;
- optionally wherein the cancer is a head and neck squamous cell carcinoma (HNSCC), a recurrent HNSCC, a metastatic HNSCC, or a human papillomavirus (HPV)-negative HNSCC.
66-68. (canceled)
(canceled)
72-73. (canceled)
78-88. (canceled)
(canceled)
93-95. (canceled)
(canceled)
Dependencies are inferred from the claim text.